Cover Image
市場調查報告書

產前診斷:侵入性檢驗、非侵入性檢驗,及妊娠毒血症、早期陣痛的母體篩檢手法的增加

Prenatal Diagnostics: Invasive Testing, Noninvasive Testing, and Rising Maternal Screening Methods for Preeclampsia and Preterm Labor

出版商 Insight Pharma Reports 商品編碼 291114
出版日期 內容資訊 英文 140 Pages
訂單完成後即時交付
價格
Back to Top
產前診斷:侵入性檢驗、非侵入性檢驗,及妊娠毒血症、早期陣痛的母體篩檢手法的增加 Prenatal Diagnostics: Invasive Testing, Noninvasive Testing, and Rising Maternal Screening Methods for Preeclampsia and Preterm Labor
出版日期: 2015年04月09日 內容資訊: 英文 140 Pages
簡介

本報告提供侵入性治療(染色體分析 vs. 細胞遺傳學),及非侵入性篩檢手法的增加對孕婦健康帶來的影響相關調查、微陣列基礎的細胞遺傳學的分析與染色體分析的比較,再加上主要企業簡介,及人口統計調查結果等等,為您概述為以下內容。

摘要整理

PARTⅠ:出生前應用

第1章 侵入性檢驗

第2章 非侵入性檢驗

PARTⅡ:非侵入性出生前應用

第3章 Sequenom

  • 企業背景
  • 研究領域
  • MaterniT21 PLUS
  • MaterniT21 PLUS 檢驗
  • 競爭上的優勢
  • William Welch、Dirk van den Boom、Allan Bombard 的採訪

第4章 Verinata Health

  • 企業背景
  • The verifi出生前檢驗
  • 面臨的課題
  • 臨床評估、醫療費給付
  • 客戶回饋
  • Richard Rava 的採訪

第5章 Ariosa Diagnostics

  • 企業背景
  • Harmony Prenatal Test (非侵入性出生前檢驗)
  • 競爭上的優勢
  • 未來的嘗試
  • Tom Musci 的採訪

第6章 Natera

  • 企業背景
  • Panorama
  • 平台的改善
  • 檢驗
  • 面臨的課題
  • 競爭上的優勢
  • 未來的嘗試
  • Solomon Moshkevich 的採訪

第7章 Silicon Biosystems

  • 企業背景
  • DEPArray System
  • 面臨的課題
  • 競爭上的優勢
  • 未來的嘗試
  • Robert Proulx 的採訪

第8章 非侵入性篩檢檢驗的規格

PARTⅢ:出生前的併發症

第9章 出生前的併發症

第10章 Metabolomic Diagnostics

  • 企業背景
  • 妊娠毒血症檢驗
  • 競爭上的優勢
  • 未來的嘗試
  • Charles Garvey 的採訪

第11章 NX PharmaGen

  • 企業背景
  • NeXosome 平台
  • 競爭上的優勢
  • 未來的嘗試
  • Dr. Alan Ezrin 及 Brian Brohman 的採訪

PARTⅣ:人口統計調查

第12章 調查結果

  • 調查統計
  • 研究領域
  • 面臨的課題
  • 產前診斷所採用的應用
  • 競爭策略

在PARTⅤ:企業名錄 - 在產前診斷領域活動的企業清單

Cambridge Healthtech Institute

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

New to Insight Pharma Reports is Prenatal Diagnostics: Invasive Testing, Noninvasive Testing, and Rising Maternal Screening Methods for Preeclampsia and Preterm Labor. This report discusses improvements in invasive procedures (karyotyping vs. cytogenetics), and the rise of noninvasive screening methods and their impact on prenatal healthcare. Although covering standard invasive procedure, this report focuses on the noninvasive technologies either on the market or in development.

VIDEO DEMONSTRATION

The first chapter of this report discusses microarray-based cytogenetics and how it compares to karyotyping. Karyotyping is often the standard method used to detect chromosomal aneuploidies, but with microarray-based procedures even more aneuploidies can be detected with the same efficacy. Either method can be used in sync with noninvasive procedures that show positive screening results for aneuploidies, but microarray analysis may be more useful for copy number variations that often go undetected with karyotyping.

Highlighting noninvasive methods, several companies have come out with novel technologies that allow them to analyze fetal DNA without risk of injury to the mother or fetus. Amniocentesis and chorionic villus sampling are common methods used to analyze fetal DNA for aneuploidies but at the risk of miscarriage and infection. With noninvasive procedures, screening can be done for common aneuploidies and further analysis can be done on women with only positive results. This not only decreases the amount of unnecessary invasive testing but also the amount of unnecessary stress levels of many expecting mothers. Companies participating in this section include:

  • Sequenom
  • Verinata Health
  • Ariosa Diagnostics
  • Natera
  • Silicon Biosystems

Other areas discussed in this report include preeclampsia and preterm labor. Preeclampsia is a common condition in women and often isn't detected until later in pregnancy. It can lead to preterm labor, which may be fatal for both the fetus and the mother. So far, a test to screen for the likelihood of preeclampsia does not exist. Detecting the risk of preeclampsia early in pregnancy can allow the expecting mother to take necessary action to avoid preterm labor at all costs, decreasing any complications that may severely affect the fetus including death. Companies highlighted in this section include:

  • Metabolomic Diagnostics
  • NX PharmaGen

In addition to covering several aspects of prenatal diagnostics, this report also includes specifications of particular instruments, exclusive interviews with CEOs, CSOs, and Vice Presidents of the participating companies. Specific areas of focus include company goals, customer feedback, challenges encountered, competitive advantage, platform pricing, and future endeavors. A survey capturing the demographics of the prenatal industry is presented at the end of the report, specifically highlighting organizational background, areas of research, challenges encountered, and applications in development.

Also included is a directory of companies that were and were not interviewed for this report.

Table of Contents

Executive Summary

Part I: Prenatal Applications

CHAPTER 1: Invasive Testing

  • Karyotyping
  • Microarray analysis

CHAPTER 2: Noninvasive Testing

  • Sequence-based cell-free DNA testing
  • Fetal cell isolation

Part II: Noninvasive Prenatal Applications

CHAPTER 3: Sequenom

  • Company background
  • Areas of Research
  • MaterniT21™ PLUS
  • MaterniT21 PLUS validation
  • Competitive advantage
  • Future endeavors
  • Interview with William Welch; Dirk van den Boom; and Allan Bombard
    • Company background
    • Technologies in development
    • SEQureDx platform
    • MaterniT21 platform
    • Validation techniques
    • Areas of improvement
    • Competitive advantage
    • Customer feedback
    • Future endeavors

CHAPTER 4: Verinata Health

  • Company background
  • The verifi® prenatal test
  • Challenges encountered
  • Clinical validation and reimbursement
  • Customer feedback
  • Interview with Richard Rava
    • Company background
    • verifi® prenatal test
    • Challenges encountered
    • Competitive advantage

CHAPTER 5: Ariosa Diagnostics

  • Company background
  • Harmony Prenatal Test
  • Competitive advantage
  • Future endeavors
  • Interview with Tom Musci
    • Company background
    • Harmony Test
    • Competitive advantage
    • Future endeavors

CHAPTER 6: Natera

  • Company background
  • Panorama
  • Platform improvements
  • Validation
  • Challenges encountered
  • Competitive advantage
  • Future endeavors
  • Interview with Solomon Moshkevich
    • Company background
    • Panorama
    • Platform improvements
    • Validation
    • Challenges encountered
    • Customer feedback
    • Competitive advantage
    • Future endeavors

CHAPTER 7: Silicon Biosystems

  • Company background
  • DEPArray System
  • Challenges encountered
  • Competitive advantage
  • Future endeavors
  • Interview with Robert Proulx
    • Company background
    • DEPArray Platform
    • Challenges encountered
    • Customer feedback
    • Future endeavors

CHAPTER 8: Noninvasive Screening Test Specifications

Part III: Prenatal Complications

CHAPTER 9: Prenatal Complications

  • Preeclampsia
  • Preterm labor

CHAPTER 10: Metabolomic Diagnostics

  • Company background
  • Preeclampsia screening test
  • Competitive advantage
  • Future endeavors
  • Interview with Charles Garvey
    • Company background
    • Areas of research
    • Competitive advantage
    • Future endeavors

CHAPTER 11: NX PharmaGen

  • Company background
  • NeXosome platform
  • Competitive advantage
  • Future endeavors
  • Interview questions with Dr. Alan Ezrin and Brian Brohman
    • Company background
    • Preterm labor assays
    • Challenges encountered
    • Competitive advantage
    • Future endeavors

Part IV: Demographic Survey

CHAPTER 12: Survey Results

  • Survey demographics
  • Areas of research
  • Challenges encountered
  • Applications being used for prenatal diagnostics
  • Competitive strategies

Part V: Company Directory: A list of companies working in Prenatal Diagnostics

References

About Cambridge Healthtech Institute

Figures:

  • Figure 12.1: Survey demographics
  • Figure 12.2: Screening vs. testing
  • Figure 12.3: Specific areas of research
  • Figure 12.4: Challenges encountered
  • Figure 12.5: Preferred applications of use
  • Figure 12.6: Competitive strategies

Tables:

  • Table 3.1: MaterniT21 PLUS aneuploidy performance
  • Table 3.2: MaterniT21 PLUS
  • Table 4.1: verifi prenatal test performance for aneuploidies
  • Table 4.2: verifi prenatal test performance for sex chromosomes
  • Table 4.3: verifi prenatal test
  • Table 5.1 Harmony Test
  • Table 6.1: Panorama Test
  • Table 7.1: DEPArray System
  • Table 8.1: Noninvasive screening test specifications
Back to Top